Neurostimulation for Parkinson's disease with early motor complications.

BACKGROUND: Subthalamic stimulation reduces motor disability and improves quality of life in patients with advanced Parkinson's disease who have severe levodopa-induced motor complications. We hypothesized that neurostimulation would be beneficial at an earlier stage of Parkinson's disease. METHODS: In this 2-year trial, we randomly assigned 251 patients with Parkinson's disease and early motor complications (mean age, 52 years; mean duration of disease, 7.5 years) to undergo neurostimulation plus medical therapy or medical therapy alone. The primary end point was quality of life, as assessed with the use of the Parkinson's Disease Questionnaire (PDQ-39) summary index (with scores ranging from 0 to 100 and higher scores indicating worse function). Major secondary outcomes included parkinsonian motor disability, activities of daily living, levodopa-induced motor complications (as assessed with the use of the Unified Parkinson's Disease Rating Scale, parts III, II, and IV, respectively), and time with good mobility and no dyskinesia. RESULTS: For the primary outcome of quality of life, the mean score for the neurostimulation group improved by 7.8 points, and that for the medical-therapy group worsened by 0.2 points (between-group difference in mean change from baseline to 2 years, 8.0 points; P=0.002). Neurostimulation was superior to medical therapy with respect to motor disability (P<0.001), activities of daily living (P<0.001), levodopa-induced motor complications (P<0.001), and time with good mobility and no dyskinesia (P=0.01). Serious adverse events occurred in 54.8% of the patients in the neurostimulation group and in 44.1% of those in the medical-therapy group. Serious adverse events related to surgical implantation or the neurostimulation device occurred in 17.7% of patients. An expert panel confirmed that medical therapy was consistent with practice guidelines for 96.8% of the patients in the neurostimulation group and for 94.5% of those in the medical-therapy group. CONCLUSIONS: Subthalamic stimulation was superior to medical therapy in patients with Parkinson's disease and early motor complications. (Funded by the German Ministry of Research and others; EARLYSTIM ClinicalTrials.gov number, NCT00354133.).

Clinical identification of dysarthria types among neurologists, residents in neurology and speech therapists.

BACKGROUND: Classification of dysarthria types comprises flaccid, spastic, ataxic, hypo- and hyperkinetic and mixed dysarthria. This study focussed on the ability of neurologists to clinically identify the correct type of dysarthria in neurological patients. METHODS: Eighteen patients with dysarthria and 4 healthy controls were enrolled in the study. The gold standard for dysarthria type was the underlying neurological disease. Recordings of a standard reading passage and free speech were made. Raters were neurologists, residents in neurology and speech therapists, whose scores were compared. RESULTS: Neurologists correctly identified 40% of the recordings, residents 41%, and speech therapists 37%. Interrater agreement was fair among all 3 groups; intrarater agreement was fair to moderate. CONCLUSION: This study suggests that neurologists should be aware of the unreliability of identifying the dysarthria type without the use of additional validated instruments or rating scales in a clinical setting.

[More rapid transfer to an additional-care facility]. / Sneller doorplaatsen naar een vervolgvoorziening.

Elderly patients admitted to a hospital ward often need additional care after discharge. Waiting for this additional care often leads to blocked beds. The administrative procedures for transferring patients to additional-care facilities require about 10 days. The main reason for this delay is the time needed by the regional indicating office (RIO) to do their assessment and to give approval. There are various possible ways to make the discharge procedure more efficient. Should the available capacity within the facilities be the only delaying factor, then this would constitute a task for the regional care office.

Predictors of health care use in patients with Parkinson's disease: a longitudinal study.

PURPOSE: To predict health care use in patients with Parkinson's disease. METHODS: The health care use of 235 patients with Parkinson's disease was studied twice over the course of 1 year. Use consisted of visits to the neurologist and general practitioner (GP) and use of a physiotherapist, a psychotherapist, or home care nurse. The effects of both prior and concurrent sociodemographic, disease-related, and psychosocial characteristics on health care use were examined. RESULTS: Patients who were living with others and patients with private health insurance paid significantly (p <0.01) more visits to their neurologists. For visits to the general practitioner, disease severity and poor quality of life, as measured by the Parkinson's Disease Quality of Life questionnaire (PDQL), were the most important predictors. Other sociodemographic and disease-related characteristics, such as age, gender, and disease duration, were not related to doctor visits. Physiotherapy was associated with disease severity and poor quality of life. Lack of social support, depression, and poor quality of life were correlated with psychotherapy, whereas age, female gender, living alone, disease severity, and disease duration were related to use of a home care nurse. CONCLUSIONS: The number of visits to a neurologist by patients with PD is not associated with disease severity or quality of life impairment, but only with sociodemographic characteristics. Nonmedical care is predicted by disease severity and psychosocial characteristics. The consequences for care and costs are discussed.

Treatment of cervical dystonia: a comparison of measures for outcome assessment.

UNLABELLED: There is little agreement on which outcome measures to use to express the efficacy of treatments for cervical dystonia. We analyzed change scores on various scales of 64 new patients with cervical dystonia before and after repeated injections with botulinum toxin. METHOD: The association between change in impairment (Tsui), and change in pain (TWSTRS-Pain) and functional health (TWSTRS-D, MOS-20) was expressed in percentages of variance explained. Effect sizes of the outcome measures from patients who continued botulinum treatment and dropouts were compared. Performance of outcome measures to distinguish patients who continued treatment and dropouts was analyzed with ROC curves and areas under the curve (AUC). RESULTS: Impairments explained < or =7% of the score variance in functional health. There were no differences between the effect sizes of impairment and pain of patients who continued treatment and dropouts (p > 0.60). This suggests a poor reflection of the treatment efficacy by these outcome measures. Conversely, there were significant differences between the effect sizes of the functional status scales of the patients who continued treatment and the dropouts (p < or = 0.01). ROC curve analysis showed that the disability, handicap, and global disease burden scale accurately distinguished between the two groups (AUCs > 0.80). Impairments showed no discriminative accuracy (AUC = 0.46). CONCLUSION: Neurologic impairments have a small impact on the functional health of cervical dystonia patients. Disability, handicap, and a global measure of disease burden were the most suitable outcome parameters to express the clinical efficacy of botulinum therapy.

Haematuria: intravenous urography, ultrasound or both?

PURPOSE: To compare the diagnostic value of intravenous urography (IVU), ultrasound (US) and their combination in detecting upper urinary tract malignancies in patients with haematuria. MATERIALS AND METHODS: In a prospective study, 360 consecutive patients who consulted the urologist for haematuria without renal colic were scheduled for IVU and US on the same day. The two procedures were performed by two different radiologists and reported independently. Histology or clinical follow-up of one year served as the gold standard. RESULTS: 63 patients dropped out. Of the remaining 297 patients, 9 (3%) had a malignancy in the upper urinary tract. Sensitivity and specificity with regard to the upper urinary tract pathology were 67% and 91% for IVU and 56% and 94% for US, respectively. For both techniques combined this was 79% and 88%, respectively. CONCLUSION: An acceptable sensitivity for detecting upper urinary tract malignancies is obtained only by combining IVU and US.

Late presentation of congenital muscular torticollis: a non-dystonic cause of torticollis.

We describe three patients with a late presentation of congenital muscular torticollis to emphasize that this non-dystonic type of torticollis has to be considered in the differential diagnosis of cervical dystonia, even in adult patients. Surgery is the treatment of choice. Postoperatively, two of our patients had a transient lesion of the accessory nerve. We assume that in our patients the accessory nerve was embedded in the fibrous tissue around the affected muscle. To prevent damage to the accessory nerve, the incision has to be made distally at about 1 cm above the clavicle.

Blink reflex recovery curves in blepharospasm, torticollis spasmodica, and hemifacial spasm.

R1 and R2 blink reflex responses to single and paired stimuli were investigated in 23 control subjects, 21 patients with blepharospasm (BSP), 20 patients with torticollis spasmodica (TS), and 23 with hemifacial spasm (HFS). For paired stimuli, we compared measurements of area and peak responses at two and three times R2 threshold. R1 and R2 indices were calculated as the average of the recovery values at 0.5-, 0.3-, and 0.21-s interstimulus intervals to test individual patients. Peak amplitude measurements at three times R2 threshold were optimal. The R2 index was abnormal in 67% of BSP patients, 37% of TS patients, and 50% of HFS patients on the affected side and 20% on the unaffected side. A normal R2 index in one third of patients with BSP may indicate that different pathophysiological mechanisms are involved in this type of focal dystonia.

CT and MR assessment of tumors of the nose and paranasal sinuses, the nasopharynx and the parapharyngeal space using ROC methodology.

Neoplastic disease of the nose and paranasal sinuses, the nasopharynx and the parapharyngeal space requires thorough assessment of location and extension in order to plan appropriate treatment. This study evaluates computer tomography and magnetic resonance imaging in the workup of malignant and non-malignant tumors of the nose and paranasal sinuses, the nasopharynx and the parapharyngeal space in 76 patients. An attempt is made to characterize histopathology on magnetic resonance images by analyzing the signal intensities on T1- and T2-weighted images relative to muscle and brain tissue. The test performance of computer tomography and magnetic resonance imaging in the assessment of tumor extension are compared with receiver operating characteristic methodology. Although no definitive conclusions can be made as to the histopathology on the basis of the signal intensities on magnetic resonance imaging, some tumors show characteristic images. Receiver operating characteristic analysis of the performance of computer tomography and magnetic resonance imaging in the assessment of extension of neoplastic disease of the nose and paranasal sinuses, the nasopharynx and the parapharyngeal space, demonstrates no statistically significant difference in overall test performance. However, in evaluating regions involving predominantly soft tissue structures and comparatively large bony structures magnetic resonance imaging is superior to computer tomography, whereas in evaluating regions involving thin bony structures, computer tomography performs better than magnetic resonance imaging.

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment.

OBJECTIVE: To assess the incidence of the AIDS dementia complex and the presence of HIV I p24 antigen in cerebrospinal fluid in relation to zidovudine treatment. DESIGN: Retrospective study of a consecutive series of patients with AIDS from 1982 to 1988. SETTING: An academic centre for AIDS. PATIENTS: 196 Patients with AIDS and neurological symptoms examined from 1982 to 1988. INTERVENTIONS: Zidovudine treatment, which was introduced to The Netherlands on 1 May 1987 for patients with severe symptoms of HIV infection (Centers for Disease Control groups IVA, B, C, and D). MAIN OUTCOME MEASURES: Diagnosis of AIDS dementia complex and presence of HIV I p24 antigen in cerebrospinal fluid. RESULTS: The AIDS dementia complex was diagnosed in 40 of the 196 (20%) patients with AIDS. Thirty eight of 107 patients with AIDS (36%) not taking zidovudine developed the AIDS dementia complex compared with two of the 89 (2%) taking the drug (p less than 0.00001). The incidence of the AIDS dementia complex increased to 53% in the first half of 1987, after the introduction of zidovudine in May 1987, decreasing to 10% in the second half of 1987 and to 3% in 1988. Dementia was diagnosed before definition of the AIDS dementia complex (1986) according to DSM-III criteria and there was good agreement between diagnosis before and after 1986. Sixteen of 61 samples of cerebrospinal fluid (26%) from patients with AIDS (10 with the AIDS dementia complex) not taking zidovudine were positive for HIV I p24 antigen, whereas none of 37 cerebrospinal fluid samples from patients with AIDS (two with the AIDS dementia complex) taking zidovudine were positive. CONCLUSIONS: The incidence of AIDS dementia complex in patients with AIDS declined after the introduction of systematic treatment with zidovudine; the AIDS dementia complex might be prevented by inhibiting viral replication in the central nervous system.

Tendon reflex asymmetry by voluntary mental effort in healthy subjects.

The effect of voluntary mental influences on the tendon reflexes was examined in healthy subjects. The patellar reflexes were evoked by a method comparable with the clinical examination, and the reflexes were recorded by surface electrodes. Eighteen subjects were instructed to increase and then decrease the right patellar reflex by mental effort, without contracting any muscles. Most subjects increased the reflex in both conditions. Subsequently, ten subjects were instructed to increase the right patellar reflex and decrease the left by mental effort. Measurement showed reflex asymmetry in seven subjects consistent with the instruction. The experiment was repeated in another 20 subjects with symmetric reflexes at rest. Ten of these subjects were, after random assignment, instructed to increase either the right or the left knee jerk. All subjects (and an additional 15 asymmetric control subjects) were examined by a neurologist without knowledge of the instruction. Three of the ten instructed subjects were correctly judged to be asymmetric, but the agreement between instruction and neurologic judgment was not statistically significant. Mentally induced reflex asymmetry is possible, and may be clinically relevant in some cases.

Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection.

Human immunodeficiency virus antigen (HIV-Ag) was detected in the serum of most adult (13/16) and paediatric (6/6) AIDS patients and rarely in the serum of symptomless seropositive controls (1/13). It was present in the cerebrospinal fluid (CSF) of all 5 children and most (5/9) adults with AIDS-related encephalopathy, but not in the CSF of 13 symptomless seropositive controls, of whom 8 had antibody in the CSF. A longitudinal study of 1 of the controls with antibody in the CSF showed that HIV-Ag in CSF was present transiently before the occurrence of antibody in the CSF. In serial samples of serum from 35 men who seroconverted HIV-Ag was detected in 11 persons--in 5 before seroconversion and in 6 after. 3 of the 6 who became antigenaemic after seroconversion remained so for the rest of the follow-up. AIDS was diagnosed in 1 patient, 3 months after HIV-Ag was first detected in serum and 6 months after seroconversion. The findings suggest that HIV-Ag appears early and transiently in primary HIV infection. Antibody production follows, after which HIV-Ag may disappear. Its persistence or reappearance seems to correlate with clinical, immunological, and neurological deterioration.